DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Rebif (Interferon Beta-1A) - Deafness Unilateral - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Deafness Unilateral ()

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Rebif (Interferon Beta-1A) where reactions include deafness unilateral. The selected reports were submitted to the FDA during the sample period of about a year.

Possible Rebif side effects in female

Reported by a consumer/non-health professional from United States on 2012-06-29

Patient: female

Reactions: Inappropriate Schedule of Drug Administration, Vomiting, Fatigue, Deafness Unilateral, Central Nervous System Lesion, Dizziness

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Rebif
    Indication: Multiple Sclerosis
    Start date: 2012-04-18

Rebif
    End date: 2012-06-01

Rebif



Possible Rebif side effects in male

Reported by a physician from United States on 2012-05-02

Patient: male

Reactions: Deafness Unilateral

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Rebif



Possible Rebif side effects in male

Reported by a physician from United States on 2012-04-13

Patient: male

Reactions: Heart Rate Decreased, Deafness Unilateral, Central Nervous System Lesion, Injection Site Urticaria, Atrial Fibrillation

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Atropine
    Indication: Heart Rate Decreased
    Start date: 2012-03-01

Rebif
    Start date: 2012-03-01

Rebif
    Indication: Multiple Sclerosis
    Start date: 2012-02-27
    End date: 2012-03-01



Possible Rebif side effects in male

Reported by a consumer/non-health professional from United States on 2012-04-05

Patient: male

Reactions: Heart Rate Decreased, Central Nervous System Lesion, Deafness Unilateral, Injection Site Urticaria, Atrial Fibrillation

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Atropine
    Indication: Heart Rate Decreased
    Start date: 2012-03-01

Rebif
    Indication: Product Used FOR Unknown Indication
    Start date: 2012-02-27
    End date: 2012-03-01

Rebif
    Start date: 2012-03-01



Possible Rebif side effects in female

Reported by a consumer/non-health professional from United States on 2012-03-27

Patient: female

Reactions: Deafness Unilateral, Vertigo, Inner Ear Disorder, Lethargy, Multiple Sclerosis Relapse

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Rebif



Possible Rebif side effects in female

Reported by a consumer/non-health professional from United States on 2012-02-24

Patient: female

Reactions: Deafness Unilateral, Central Nervous System Lesion, Feeling Abnormal

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Rebif



Possible Rebif side effects in female

Reported by a consumer/non-health professional from United States on 2011-12-20

Patient: female

Reactions: Deafness Unilateral, Injection Site Atrophy, Vertigo, Anger, Injection Site Pain, Influenza Like Illness

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Rebif

Other drugs received by patient: Anxiety Medicine



Possible Rebif side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2011-10-28

Patient: female

Reactions: Deafness Unilateral, Urinary Tract Infection, Cystopexy, Brain Operation

Drug(s) suspected as cause:
Rebif

Other drugs received by patient: Diltiazem HCL; Gabapentin; Omeprazole



Possible Rebif side effects in female

Reported by a individual with unspecified qualification from United States on 2011-10-20

Patient: female, weighing 63.0 kg (138.6 pounds)

Reactions: Vomiting, Nausea, Incorrect Dose Administered, Abdominal Discomfort, Dysacusis, Balance Disorder, Deafness Unilateral, Vertigo, Dizziness

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Gilenya
    Dosage: 0.5 mg, qod
    Administration route: Oral
    End date: 2011-02-21

Gilenya
    Dosage: 0.5 mg, daily
    Administration route: Oral
    Indication: Multiple Sclerosis
    Start date: 2011-02-11
    End date: 2011-02-12

Rebif
    Dosage: unk ukn, unk

Other drugs received by patient: Vesicare; Kariva 28

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014